WO2022195797A1 - 末端シアル酸残基がα2,6結合でガラクトースに結合した糖鎖に特異的に結合するモノクローナル抗体、及び、末端シアル酸残基がα2,6結合でガラクトースに結合した糖鎖の測定方法 - Google Patents
末端シアル酸残基がα2,6結合でガラクトースに結合した糖鎖に特異的に結合するモノクローナル抗体、及び、末端シアル酸残基がα2,6結合でガラクトースに結合した糖鎖の測定方法 Download PDFInfo
- Publication number
- WO2022195797A1 WO2022195797A1 PCT/JP2021/011037 JP2021011037W WO2022195797A1 WO 2022195797 A1 WO2022195797 A1 WO 2022195797A1 JP 2021011037 W JP2021011037 W JP 2021011037W WO 2022195797 A1 WO2022195797 A1 WO 2022195797A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amino acid
- acid sequence
- antibody
- seq
- sugar chain
- Prior art date
Links
- 229930182830 galactose Natural products 0.000 title claims abstract description 42
- 238000000034 method Methods 0.000 title claims description 21
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical group CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 title claims description 10
- 125000005629 sialic acid group Chemical group 0.000 claims abstract description 26
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims abstract description 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 79
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 59
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 59
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 7
- 238000010494 dissociation reaction Methods 0.000 claims description 6
- 230000005593 dissociations Effects 0.000 claims description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 239000012634 fragment Substances 0.000 abstract description 2
- 239000000427 antigen Substances 0.000 description 20
- 102000036639 antigens Human genes 0.000 description 20
- 108091007433 antigens Proteins 0.000 description 20
- 239000000523 sample Substances 0.000 description 14
- 238000002965 ELISA Methods 0.000 description 12
- 102000004190 Enzymes Human genes 0.000 description 11
- 108090000790 Enzymes Proteins 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 241000283973 Oryctolagus cuniculus Species 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
- 238000000691 measurement method Methods 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 239000007787 solid Substances 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 238000001514 detection method Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 4
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 4
- 238000003018 immunoassay Methods 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- -1 polypropylene Polymers 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 102000004856 Lectins Human genes 0.000 description 3
- 108090001090 Lectins Proteins 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 239000002523 lectin Substances 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000863 peptide conjugate Substances 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- 238000007860 single-cell PCR Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 102000005348 Neuraminidase Human genes 0.000 description 2
- 108010006232 Neuraminidase Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 240000006028 Sambucus nigra Species 0.000 description 2
- 235000003142 Sambucus nigra Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 210000000628 antibody-producing cell Anatomy 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- 239000000562 conjugate Substances 0.000 description 2
- 235000008995 european elder Nutrition 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- GVJXGCIPWAVXJP-UHFFFAOYSA-N 2,5-dioxo-1-oxoniopyrrolidine-3-sulfonate Chemical compound ON1C(=O)CC(S(O)(=O)=O)C1=O GVJXGCIPWAVXJP-UHFFFAOYSA-N 0.000 description 1
- OBYNJKLOYWCXEP-UHFFFAOYSA-N 2-[3-(dimethylamino)-6-dimethylazaniumylidenexanthen-9-yl]-4-isothiocyanatobenzoate Chemical compound C=12C=CC(=[N+](C)C)C=C2OC2=CC(N(C)C)=CC=C2C=1C1=CC(N=C=S)=CC=C1C([O-])=O OBYNJKLOYWCXEP-UHFFFAOYSA-N 0.000 description 1
- HSTOKWSFWGCZMH-UHFFFAOYSA-N 3,3'-diaminobenzidine Chemical compound C1=C(N)C(N)=CC=C1C1=CC=C(N)C(N)=C1 HSTOKWSFWGCZMH-UHFFFAOYSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 108010000239 Aequorin Proteins 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- XPDXVDYUQZHFPV-UHFFFAOYSA-N Dansyl Chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001524178 Paenarthrobacter ureafaciens Species 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 125000000837 carbohydrate group Chemical group 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012866 crystallographic experiment Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000011984 electrochemiluminescence immunoassay Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000002875 fluorescence polarization Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 229920002102 polyvinyl toluene Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 239000000941 radioactive substance Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 150000004043 trisaccharides Chemical group 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57469—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving tumor associated glycolinkage, i.e. TAG
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
- G01N2400/02—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates involving antibodies to sugar part of glycoproteins
Definitions
- the present invention provides a monoclonal antibody that specifically binds to a sugar chain having a terminal sialic acid residue linked to galactose via an ⁇ 2,6 bond, and a sugar chain having a terminal sialic acid residue linked to galactose via an ⁇ 2,6 bond. Regarding the measurement method.
- the sugar chain of PSA (Prostate Specific Antigen), which is known as a marker for prostate cancer, is a two-chain N-type sugar chain in which sialic acid at the end is linked to galactose with an ⁇ 2,6 bond, and a sialic acid at the end It is known that there are N-type sugar chains that are linked to galactose via ⁇ 2,3 bonds, and that the number of sugar chains that are linked to galactose via ⁇ 2,3 bonds increases with carcinogenesis. (Non-Patent Document 1).
- Sambucus nigra lectin is known as a probe capable of detecting sugar chains with terminal sialic acid residues bound to galactose via ⁇ 2,6 bonds, and is used as a probe for detecting sugar chains containing sialic acid.
- Patent Document 1 In addition, using a glycolipid having a sugar chain with a terminal sialic acid residue linked to galactose via an ⁇ 2,6 bond as an immunogen, a mouse monoclonal that recognizes a sugar chain with a terminal sialic acid residue linked to galactose via an ⁇ 2,6 bond was used. An antibody has been reported (Patent Document 2).
- Sambucus nigra lectin is a plant-derived natural product that serves as a raw material, and its binding property varies depending on product lots. Recombinant lectins are being developed, but have yet to be put to practical use. In addition, detection of cancerous transformation of PSA requires antibodies with higher sensitivity that recognize sugar chains in which terminal sialic acid residues are linked to galactose via ⁇ 2,6 linkages.
- the present invention has been made in view of the above problems, and an object of the present invention is to provide a monoclonal antibody having a high binding property to a sugar chain in which a terminal sialic acid residue is linked to galactose via an ⁇ 2,6 bond, and a monoclonal antibody having a terminal sialic acid residue.
- An object of the present invention is to provide a method for measuring a sugar chain in which an acid residue is linked to galactose via an ⁇ 2,6 bond.
- the present inventors immunized a rabbit with Sia ⁇ 2-6Gal ⁇ 1-4GlcNAc-BSA as an immunogen, isolated the resulting positive rabbit B cells, obtained antibody genes by single-cell PCR, and transferred the antibody genes to the host.
- the inventors have found that a monoclonal antibody obtained by introduction into cells binds with high affinity to sugar chains whose terminal sialic acid residues are bound to galactose via ⁇ 2,6 linkages, thereby completing the present invention.
- the present invention includes the following aspects.
- the binding property to a sugar chain in which a terminal sialic acid residue is linked to galactose via an ⁇ 2,6 bond is 20% higher than that to a sugar chain in which a terminal sialic acid residue is linked to galactose via an ⁇ 2,3 bond.
- the amino acid sequence of complementarity determining region (hereinafter also referred to as CDR) 1 of the heavy chain variable region (hereinafter also referred to as VH) of the antibody or antibody fragment thereof is represented by SEQ ID NO: 1.
- VH CDR2 amino acid sequence comprises the amino acid sequence represented by SEQ ID NO: 2
- VH CDR3 amino acid sequence comprises the amino acid sequence represented by SEQ ID NO: 3
- the light chain variable region The amino acid sequence of CDR1 of VL includes the amino acid sequence represented by SEQ ID NO: 4
- the amino acid sequence of CDR2 of VL includes the amino acid sequence represented by SEQ ID NO: 5
- the monoclonal antibody or antibody fragment thereof according to any one of [1] to [3], wherein the sequence comprises the amino acid sequence represented by SEQ ID NO:6.
- VH amino acid sequence of the antibody or antibody fragment thereof comprises the amino acid sequence represented by SEQ ID NO: 13
- VL amino acid sequence comprises the amino acid sequence represented by SEQ ID NO: 14; A monoclonal antibody or antibody fragment thereof as described.
- the VH CDR1 amino acid sequence of the antibody or antibody fragment thereof comprises the amino acid sequence represented by SEQ ID NO: 7 and the VH CDR2 amino acid sequence comprises the amino acid sequence represented by SEQ ID NO: 8;
- the amino acid sequence of CDR3 of VH comprises the amino acid sequence represented by SEQ ID NO: 9
- the amino acid sequence of CDR1 of VL comprises the amino acid sequence represented by SEQ ID NO: 10
- the amino acid sequence of CDR2 of VL comprises the amino acid sequence of SEQ ID NO:
- the monoclonal antibody according to any one of [1] to [3], which comprises the amino acid sequence represented by 11, and the amino acid sequence of VL CDR3 comprises the amino acid sequence represented by SEQ ID NO: 12, or the antibody thereof piece.
- VH amino acid sequence of the antibody or antibody fragment thereof comprises the amino acid sequence represented by SEQ ID NO: 15
- VL amino acid sequence comprises the amino acid sequence represented by SEQ ID NO: 16
- a monoclonal antibody having a high binding property to a sugar chain in which a terminal sialic acid residue is bound to galactose via an ⁇ 2,6 bond (hereinafter also referred to as an ⁇ 2,6 sugar chain), and an ⁇ 2,6 sugar chain can provide a method for measuring
- Example 2 shows the results of a sensorgram of 8A2 antibody against a biosensor on which ⁇ 2,6 sugar chains are immobilized in Example 2.
- FIG. 2 shows the results of a sensorgram of 8A2 antibody against a biosensor on which ⁇ 2,3 sugar chains are immobilized in Example 2.
- FIG. 2 shows sensorgram results of the 8A2 antibody against a biosensor on which a sugar chain bound with galactose with no sialic acid bound at its end (hereinafter also referred to as a galactose-bound sugar chain) was immobilized in Example 2.
- FIG. 2 shows the results of a sensorgram of 8B9 antibody against a biosensor on which ⁇ 2,6 sugar chains are immobilized in Example 2.
- FIG. 2 shows the results of a sensorgram of 8B9 antibody against a biosensor on which ⁇ 2,3 sugar chains are immobilized in Example 2.
- FIG. 2 shows the results of a sensorgram of 8B9 antibody against a biosensor on which galactose-linked sugar chains are immobilized in Example 2.
- antibody refers to a full-length immunoglobulin molecule, either naturally occurring or produced by genetic recombination techniques
- antibody fragment refers to an antigen-binding fragment of such an immunoglobulin molecule.
- Antibody fragments include F(ab') 2 , F(ab) 2 , Fab', Fab, Fv, scFv, variants thereof, fusion proteins or fusion peptides containing antibody portions, and ⁇ 2,3 carbohydrate chains. Modified structures other than immunoglobulin molecules, including moieties, can be included.
- the term “antibody specifically binds” means that the terminal sialic acid residue does not substantially bind to other sugar chains different from the sugar chain bound to galactose via an ⁇ 2,6 bond. It means binding to ⁇ 2,6 sugar chains.
- ⁇ 2,6 sugar chain is also referred to as "Sia ⁇ 2-6Gal ⁇ 1-4GlcNAc”.
- the term "monoclonal antibody” means an antibody obtained from a substantially homogeneous population of antibodies, wherein the individual antibodies contained in the population are naturally occurring random antibodies that may exist in some number. Identical except for the variants.
- a monoclonal antibody is an antibody that displays one binding specificity and affinity for a particular epitope on an antigen.
- the modifier "monoclonal” indicates the properties of antibodies obtained from a substantially homogeneous antibody population and is not to be interpreted restrictively as requiring production of the antibody by a particular method.
- the "heavy chain” of an antibody refers to the larger of the two types of polypeptide chains present in all antibody molecules in their naturally occurring conformation.
- an antibody “light chain” refers to the smaller of the two types of polypeptide chains present in all antibody molecules in their naturally occurring conformation.
- the complementarity determining region is composed of a heavy chain complementarity determining region and a light chain complementarity determining region.
- the heavy and light chain variable regions each consist of three CDRs and four framework regions (FR) joined by the CDRs.
- the CDRs on each chain are held in close proximity by the FRs and, together with the CDRs on the other chain, contribute to the formation of the antigen-binding site of the antibody.
- Techniques for determining CDRs include, but are not limited to, (1) approaches based on interspecies sequence variability (e.g., Kabat et al. Sequences of Proteins of Immunological Interest, 5th ed., 1991, National Institutes of Health, Bethesda MD); and (2) approaches based on crystallographic studies of antigen-antibody complexes (Al-lazikani et al., J. Molec. Biol. 273, 927-948, 1997). can be done. These approaches and other approaches may be used in combination.
- approaches based on interspecies sequence variability e.g., Kabat et al. Sequences of Proteins of Immunological Interest, 5th ed., 1991, National Institutes of Health, Bethesda MD
- approaches based on crystallographic studies of antigen-antibody complexes Al-lazikani et al., J. Molec. Biol. 273, 927-948, 1997.
- the monoclonal antibody or antibody fragment thereof of the present invention is a monoclonal antibody or antibody fragment thereof that specifically binds to ⁇ 2,6 sugar chains and does not bind to sugar chains with galactose bound to which sialic acid is not bound at the terminal.
- the monoclonal antibody of the present invention is also referred to as an anti- ⁇ 2,6 sugar chain monoclonal antibody.
- the anti- ⁇ 2,6 sugar chain monoclonal antibody of the present invention may be a human antibody or a non-human animal antibody.
- non-human animals include mice, rats, hamsters, rabbits, goats, sheep, chickens, etc.
- Rabbit monoclonal antibodies are preferred because of their high antigen-binding properties.
- the anti- ⁇ 2,6 sugar chain monoclonal antibody or antibody fragment thereof of the present invention is a monoclonal antibody or antibody fragment thereof that does not bind to galactose-linked sugar chains.
- the binding property of the anti- ⁇ 2,6 sugar chain monoclonal antibody or antibody fragment thereof of the present invention to the ⁇ 2,6 sugar chain is preferably higher than the binding property to the ⁇ 2,3 sugar chain.
- Chain binding is 20 times or more, preferably 30 times or more, more preferably 40 times or more, still more preferably 50 times or more, particularly preferably 80 times or more, than ⁇ 2,3 sugar chain binding .
- the binding property of the anti- ⁇ 2,6 sugar chain monoclonal antibody or antibody fragment thereof of the present invention to antigens such as ⁇ 2,6 sugar chains can be expressed by the dissociation constant (KD value).
- KD value dissociation constant
- the KD value for the ⁇ 2,6 sugar chain of the anti- ⁇ 2,6 sugar chain monoclonal antibody or antibody fragment thereof of the present invention is preferably 1.0 ⁇ 10 ⁇ 8 or less, more preferably 5.0 ⁇ 10 ⁇ 9 or less. is more preferably 1.0 ⁇ 10 ⁇ 9 or less, particularly preferably 5.0 ⁇ 10 ⁇ 9 or less, for example, 8.5 ⁇ 10 ⁇ 9 or less, 8.0 ⁇ 10 ⁇ 9 or less, 7.0 ⁇ 10 ⁇ 9 or less, 6.0 ⁇ 10 ⁇ 9 or less, 4.0 ⁇ 10 ⁇ 9 or less, 3.0 ⁇ 10 ⁇ 9 or less, 2.0 ⁇ 10 ⁇ 9 or less , 9.0 ⁇ 10 ⁇ 10 or less, 8.0 ⁇ 10 ⁇ 10 or less, 7.0 ⁇ 10 ⁇ 10 or less, 6.0 ⁇ 10 ⁇ 10 or less, 4.0 ⁇ 10 ⁇ 10 or less, 3.0 ⁇ It may be 10 ⁇ 10 or less.
- the above KD value can be calculated, for example, using a biosensor on which sugar chains serving as antigens are immobilized. Specifically, a sugar chain serving as an antigen is immobilized on a biosensor, and the biosensor is immersed in an antibody solution to allow the antibody to bind to the antigen immobilized on the biosensor. Then, it is immersed in a buffer solution such as phosphate buffered saline (PBS), and the number of antibodies bound to the biosensor or the change in the wavelength shift ⁇ caused by the change in the number of antibodies dissociated from the biosensor is measured.
- PBS phosphate buffered saline
- the KD value can be calculated from the sensorgram when the concentration of is changed.
- the anti- ⁇ 2,6 sugar chain monoclonal antibody or antibody fragment thereof of the present invention can be produced using known methods. Specifically, first, a non-human animal is immunized with a conjugate of an ⁇ 2,6 sugar chain and a carrier protein as an immunogen, and the lymphocytes of the immunized non-human animal are confirmed to bind to the antigen by ELISA. Then, lymphocytes with high binding to ⁇ 2,6 sugar chains are selected.
- Non-human animals to be immunized include mice, rats, hamsters, rabbits, goats, sheep, chickens and the like.
- antibody genes are obtained from the selected lymphocytes by the single cell PCR method and amplified by the PCR method.
- ELISA is used to confirm the antigen-binding properties of the PCR amplification products.
- a PCR amplification product that has a high binding property to ⁇ 2,6 sugar chains is transfected into cells such as Human Embryonic Kidney cells 293, and the culture supernatant containing secretory antibodies is collected, and the collected sample is is confirmed by ELISA for binding to the antigen, and clones with high binding to the ⁇ 2,6 sugar chain are obtained.
- Antibody genes are obtained from the obtained clones and inserted into a vector to obtain antibody-producing cells.
- the obtained antibody-producing cells are cultured to produce and accumulate the anti- ⁇ 2,6 sugar chain monoclonal antibody or antibody fragment thereof of the present invention, and the anti- ⁇ 2,6 sugar chain monoclonal antibody or antibody fragment of the present invention is isolated from the culture. can be manufactured.
- the amino acid sequence of CDR1 of VH comprises the amino acid sequence represented by SEQ ID NO: 1, and the amino acid sequence of CDR2 of VH is represented by SEQ ID NO: 2.
- the amino acid sequence of CDR3 of VH comprises the amino acid sequence represented by SEQ ID NO: 3
- the amino acid sequence of CDR1 of VL comprises the amino acid sequence represented by SEQ ID NO: 4
- Anti- ⁇ 2,6 sugar chain monoclonal antibody 8A2 hereinafter referred to as 8A2 antibody
- 8A2 antibody an antibody fragment thereof.
- the antibody 8A2 comprises a VH comprising the amino acid sequence represented by SEQ ID NO: 13 and a VL comprising the amino acid sequence represented by SEQ ID NO: 14.
- the amino acid sequence of CDR1 of VH comprises the amino acid sequence represented by SEQ ID NO: 7
- the amino acid sequence of CDR2 of VH comprises SEQ ID NO: 8
- the VH CDR3 amino acid sequence comprises the amino acid sequence represented by SEQ ID NO: 9
- the VL CDR1 amino acid sequence comprises the amino acid sequence represented by SEQ ID NO: 10
- the anti- ⁇ 2,6 sugar chain monoclonal antibody 8B9 8B9 antibody hereinafter or an antibody fragment thereof.
- the antibody 8B9 comprises a VH comprising the amino acid sequence represented by SEQ ID NO: 15 and a VL comprising the amino acid sequence represented by SEQ ID NO: 16.
- Table 1 shows the amino acid sequences represented by SEQ ID Nos: 1 to 12 above.
- Table 2 shows the amino acid sequences represented by SEQ ID NOs: 13 to 16 above.
- the anti- ⁇ 2,6 sugar chain monoclonal antibody or antibody fragment thereof of the present invention containing these VH CDR1 to CDR3 and VL CDR1 to CDR3 can be produced using known genetic recombination techniques. Specifically, the genes encoding VH CDR1 to CDR3 and VL CDR1 to CDR3, respectively, are incorporated into a vector containing genes encoding the FR of the antibody and the constant region of the antibody, respectively, and introduced into host cells. Cells expressing the antibody can be obtained by transforming the antibody, and the cells can be produced by culturing the cells. Cells, vector types, cell types, culture conditions, and the like used for this preparation are within the technical scope of those skilled in the art, and appropriate conditions can be set as appropriate.
- Antibody fragments are also included in the monoclonal antibodies or antibody fragments thereof of the present invention.
- the number of amino acids to be deleted, substituted, inserted and/or added is one or more, and the number is not particularly limited. Current Protocols molecular Biology, John Wiley & Sons (1987-1997), Nucleic Acids Research, 10, 6487 (1982), Proc. Natl. Acad. Sci. USA, 79, 6409 (1982), Gene, 34, 315 (1985), Nucleic Acids Research, 13, 4431 (1985), Proc. Natl. Acad. Sci. USA, 82, 488 (1985)].
- the number is preferably 1 to several tens, more preferably 1 to 20, still more preferably 1 to 10, and particularly preferably 1 to 5.
- the method for measuring ⁇ 2,6 sugar chains of the present invention is a method for measuring ⁇ 2,6 sugar chains using the anti- ⁇ 2,6 sugar chain monoclonal antibody or antibody fragment thereof of the present invention.
- a method for measuring ⁇ 2,6 sugar chains using the anti- ⁇ 2,6 sugar chain monoclonal antibody or antibody fragment thereof of the present invention ⁇ 2,6 sugar chains in a sample and the anti- ⁇ 2,6 sugar chain monoclonal antibody of the present invention are used.
- a labeled antibody or labeled antibody fragment in which a label is bound to the anti- ⁇ 2,6 sugar chain monoclonal antibody or antibody fragment thereof is added, and the ⁇ 2,6 sugar chain, the anti- ⁇ 2 ,6 sugar chain monoclonal antibody or antibody fragment thereof, and the labeled antibody or the labeled antibody fragment immune complex is generated, and the amount of label in the generated immune complex is measured ⁇ 2,6 in the sample
- An immunological measurement method for sugar chains and the like are included.
- the specimen may be blood such as serum, plasma or whole blood of animals including humans, lymph, interstitial fluid, cerebrospinal fluid, and body cavities. fluids, digestive fluids, nasal mucus, tears, sweat, urine, and the like.
- the sample may be a sample itself collected from a subject, or may be a sample obtained by subjecting the collected sample to processing such as dilution and concentration that are normally performed.
- the sample may be one collected or prepared during the execution of the measurement method, or one previously collected or prepared and stored.
- the immunological measurement method includes enzyme immunoassay (EIA or ELISA), radioimmunoassay (RIA), fluorescence immunoassay (FIA), fluorescence polarization immunoassay (FPIA), chemiluminescence immunoassay (CLIA), depending on the labeling of the labeled detection antibody. ), electrochemiluminescence immunoassay, and the like, and any of these can be used in the measurement method of the present invention, but ELISA is preferable because it allows simple and rapid measurement of the target to be detected.
- the ⁇ 2,6 sugar chain in the specimen can be measured by measuring the label in the immune complex.
- an ⁇ 2,6 sugar chain in a specimen can be measured by reacting an enzyme as a label with a substrate of the enzyme and measuring the absorbance of the colored product (sandwich method). .
- the unlabeled anti- ⁇ 2,6 sugar chain monoclonal antibody or antibody fragment thereof of the present invention immobilized on a solid support with the ⁇ 2,6 sugar chain in the sample
- the unlabeled anti- ⁇ 2,6 sugar chain monoclonal antibody or adding the antibody fragment (primary antibody)
- measuring the label of the secondary antibody It is also possible to measure the ⁇ 2,6 sugar chain in the specimen.
- the secondary antibody is labeled with biotin, bound with enzyme-labeled avidin or streptavidin to biotin, the secondary antibody is labeled with an enzyme or the like, and the label of the secondary antibody is measured.
- ⁇ 2,6 sugar chains in a sample can also be measured.
- an unlabeled anti- ⁇ 2,6 sugar chain monoclonal antibody or antibody fragment thereof may be applied to the ⁇ 2,6 sugar chain immobilized on a solid support or to a conjugate of the ⁇ 2,6 sugar chain and a protein such as BSA. is added to the solid support to generate an immune complex consisting of ⁇ 2,6 sugar chain and primary antibody, then a sample is added, and an antibody (secondary antibody) against this unlabeled antibody is labeled.
- the ⁇ 2,6 sugar chain in the sample can also be measured by adding a secondary antibody that has been modified and measuring the labeling of the standardized secondary antibody (competitive method).
- the solid support is not particularly limited as long as it can stably hold the antibody or antibody fragment.
- Preferred materials for the solid support include polymeric materials such as polystyrene, polycarbonate, polyvinyl toluene, polypropylene, polyethylene, polyvinyl chloride, nylon, polymethacrylate, gelatin, agarose, cellulose, nitrocellulose, cellulose acetate, cellulose acetate, and polyethylene terephthalate. , glass, ceramics, magnetic particles and metals.
- Preferable shapes of the solid support include tubes, beads, plates, fine particles such as latex, and sticks.
- the label examples include enzymes such as peroxidase and alkaline phosphatase in ELISA, radioactive substances such as 125 I, 131 I, 35 S and 3 H in RIA, fluorescein isothiocyanate, rhodamine and dansyl chloride in FPIA, Fluorescent substances such as phycoerythrin, tetramethylrhodamine isothiocyanate, and near-infrared fluorescent materials, in the CLIA method, enzymes such as luciferase and ⁇ -galactosidase and luminescent substrates that change into luminescent substances with each enzyme, and luciferin, aequorin, etc. Luminescent substances can be used. In addition, nanoparticles such as gold colloids and quantum dots can also be used as labels.
- ELISA when the enzyme is peroxidase, 3,3'-diaminobenzidine (DAB), 3,3',5,5'-tetramethylbenzidine (TMB), O-phenylenediamine (OPD), etc. are used as the labeling enzyme substrate.
- DAB 3,3'-diaminobenzidine
- TMB 3,3',5,5'-tetramethylbenzidine
- OPD O-phenylenediamine
- pNPP p-nitropheny phosphate
- Example 1 Using Sia ⁇ 2-6Gal ⁇ 1-4GlcNAc-BSA as an immunogen, rabbits (slc: JW/CSK, 13 weeks old) were immunized, and the obtained rabbit B cells were isolated from cells (single cells) that bind to Sia ⁇ 2-6Gal ⁇ 1-4GlcNAc. Twenty-seven positive clones were selected by testing by ELISA method. Antibody genes were obtained from the selected positive clones by single-cell PCR. Human Embryonic Kidney Cells 293 cells were transfected with the obtained antibody gene sequences, and the recombinant rabbit antibodies secreted into the culture supernatant were examined for ⁇ 2,6 sugar chains and ⁇ 2,3 sugar chains.
- Example 2 After washing with PBST three times, the culture supernatant of each clone obtained in Example 1 was diluted 2-fold, 50 ⁇ l was added, and the mixture was shaken at room temperature for 1 hour. After washing with PBST three times, 50 ⁇ l of anti-Rabbit IgG HRP ( ⁇ 10000; ab97080, manufactured by abcam) was added and shaken at room temperature for 1 hour. After washing three times with PBST, 100 ⁇ l/well of TMB substrate solution (composition: 3.3′,5.5′-tetramethylbenzidine, catalog number: N301, manufactured by ThermoFisher Scientific) was added and incubated for 5 minutes. Next, 100 ⁇ l/well of 0.1N HCl was added, and absorbance at 450 nm was measured.
- TMB substrate solution composition: 3.3′,5.5′-tetramethylbenzidine, catalog number: N301, manufactured by ThermoFisher Scientific
- Example 2 Among the monoclonal antibodies obtained in Example 1, the KD values of 8A2 antibody and 8B9 antibody were calculated as follows.
- Amino reactive biosensor (AR2G; manufactured by FORTEBIO) was hydrophilized with ultrapure water, and 20 ⁇ g/mL BSA-MBS-sialic acid ⁇ (2,3) ⁇ 1,4GlcNAc antigen solution or BSA-MBS-sialic acid ⁇ (2,6) ⁇ 1,4GlcNAc antigen solution was immersed for 10 minutes to immobilize each antigen on the sensor.
- AR2G Amino reactive biosensor
- the sensor is immersed in an EDC-/sNHS solution (composition: a 1:1 mixture of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (manufactured by FORTEBIO) and sulfo-N-hydroxysuccinimide (manufactured by FORTEBIO)), blocked.
- EDC-/sNHS solution composition: a 1:1 mixture of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (manufactured by FORTEBIO) and sulfo-N-hydroxysuccinimide (manufactured by FORTEBIO)
- the BSA-MBS- ⁇ 1,4GlcNAc antigen-immobilized sensor was treated with a sialidase solution (composition: 3 ⁇ L ⁇ (2 ⁇ 3,6,8,9) Neuraminidase from Arthrobacter ureafaciens (N3786-1SET, manufactured by Sigma) + 47 ⁇
- the biosensor was immersed in each antibody solution of 3.75 to 60 nM at 30° C. for 300 seconds to measure the binding state of the antibody to the antigen. After that, it was immersed in PBS for 300 seconds, and the state of dissociation of the antibody from the antigen was measured.
- a change in wavelength shift ⁇ caused by a change in the number of antibodies bound to the biosensor or dissociated from the biosensor was measured in real time to generate a reaction profile on the Octet system (manufactured by FORTEBIO).
- the KD value was calculated from the sensorgrams of binding and dissociation obtained in antibody solutions with concentrations ranging from 3.75 nM to 60 nM. Table 3 shows the calculated KD values. The results of the above sensorgrams for the 8A2 antibody and 8B9 antibody are shown in FIGS. 2A to 2C and 3A to 3C, respectively.
- the KD value for the ⁇ 2,6 sugar chain of the 8B9 antibody is 8.5 ⁇ 10 -9 ⁇ 2.7 ⁇ 10 -24 , whereas ⁇ 2
- the KD value for the ,3 sugar chain was 9.6 ⁇ 10 ⁇ 7 ⁇ 00. That is, the binding ability of the 8B9 antibody to ⁇ 2,6 sugar chains was 88.5 times higher than that to ⁇ 2,3 sugar chains.
- FIG. 3C no binding to galactose-linked sugar chains was observed.
- a monoclonal antibody or an antibody fragment thereof with high binding ability to ⁇ 2,6 sugar chains and a method for measuring ⁇ 2,6 sugar chains are provided.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- General Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
また、PSAの癌化の検出には、より高感度で、末端シアル酸残基がα2,6結合でガラクトースに結合した糖鎖を認識する抗体が必要である。
本発明は以下の態様を含む。
[2]末端シアル酸残基がα2,6結合でガラクトースに結合した糖鎖との解離定数が、1.0×10-8以下である、[1]に記載のモノクローナル抗体又はその抗体断片。
[3]末端シアル酸残基がα2,6結合でガラクトースに結合した糖鎖との結合性が、末端シアル酸残基がα2,3結合でガラクトースに結合した糖鎖との結合性よりも20倍以上高い、[1]又は[2]に記載のモノクローナル抗体又はその抗体断片。
[4]前記抗体又はその抗体断片の重鎖可変領域(以下、VHとも称する)の相補性決定領域(Complementarity determining region;以下、CDRとも称する)1のアミノ酸配列が、配列番号1で表されるアミノ酸配列を含み、VHのCDR2のアミノ酸配列が、配列番号2で表されるアミノ酸配列を含み、VHのCDR3のアミノ酸配列が、配列番号3で表されるアミノ酸配列を含み、軽鎖可変領域(以下、VLとも称する)のCDR1のアミノ酸配列が、配列番号4で表されるアミノ酸配列を含み、VLのCDR2のアミノ酸配列が、配列番号5で表されるアミノ酸配列を含み、VLのCDR3のアミノ酸配列が、配列番号6で表されるアミノ酸配列を含む、[1]~[3]のいずれか1項に記載のモノクローナル抗体又はその抗体断片。
[5]前記抗体又はその抗体断片のVHのアミノ酸配列が、配列番号13で表されるアミノ酸配列を含み、VLのアミノ酸配列が、配列番号14で表されるアミノ酸配列を含む、[4]に記載のモノクローナル抗体又はその抗体断片。
[6]前記抗体又はその抗体断片のVHのCDR1のアミノ酸配列が、配列番号7で表されるアミノ酸配列を含み、VHのCDR2のアミノ酸配列が、配列番号8で表されるアミノ酸配列を含み、VHのCDR3のアミノ酸配列が、配列番号9で表されるアミノ酸配列を含み、VLのCDR1のアミノ酸配列が、配列番号10で表されるアミノ酸配列を含み、VLのCDR2のアミノ酸配列が、配列番号11で表されるアミノ酸配列を含み、VLのCDR3のアミノ酸配列が、配列番号12で表されるアミノ酸配列を含む、[1]~[3]のいずれか1項に記載のモノクローナル抗体又はその抗体断片。
[7]前記抗体又はその抗体断片のVHのアミノ酸配列が、配列番号15で表されるアミノ酸配列を含み、VLのアミノ酸配列が、配列番号16で表されるアミノ酸配列を含む、[6]に記載のモノクローナル抗体又はその抗体断片。
[8][1]~[7]のいずれか1項に記載のモノクローナル抗体又はその抗体断片を用いる、末端シアル酸残基がα2,6結合でガラクトースに結合した糖鎖の測定方法。
<モノクローナル抗体及びその抗体断片>
本明細書において「抗体」とは、天然に存在するか、遺伝子組換え技術によって産生される、全長の免疫グロブリン分子をいい、「抗体断片」とはかかる免疫グロブリン分子の抗原結合性の断片をいう。かかる抗体および抗体断片は、慣用技術を用いて作製することができる。抗体断片としては、F(ab’)2、F(ab)2、Fab’、Fab、Fv、scFv、それらの変異体、抗体部分を含む融合タンパク質又は融合ペプチド、及び、α2,3糖鎖結合部位を含む、免疫グロブリン分子以外の修飾構造体等を挙げることができる。
ここで、相補性決定領域(CDR)とは、重鎖相補性決定領域および軽鎖相補性決定領域で構成される。重鎖及び軽鎖の可変領域は、それぞれ、3つのCDRと、CDRにより連結される4つのフレームワーク領域(FR)からなる。各鎖におけるCDRは、FRにより、近傍に保持されており、他方の鎖におけるCDRと共に、抗体の抗原結合部位の形成に寄与している。
本発明の抗α2,6糖鎖モノクローナル抗体又はその抗体断片の、α2,6糖鎖との結合性は、α2,3糖鎖との結合性よりも高いことが好ましく、例えば、α2,6糖鎖との結合性が、α2,3糖鎖との結合性の20倍以上、好ましくは、30倍以上、より好ましくは40倍以上、さらに好ましくは50倍以上、特に好ましくは80倍以上である。
本発明のα2,6糖鎖の測定方法は、本発明の抗α2,6糖鎖モノクローナル抗体又はその抗体断片を用いる、α2,6糖鎖の測定方法である。本発明の抗α2,6糖鎖モノクローナル抗体又はその抗体断片を用いる、α2,6糖鎖の測定方法としては、検体中のα2,6糖鎖と、本発明の抗α2,6糖鎖モノクローナル抗体又はその抗体断片とを反応させた後、前記抗α2,6糖鎖モノクローナル抗体又はその抗体断片に標識が結合した標識化抗体又は標識化抗体断片を添加し、α2,6糖鎖、前記抗α2,6糖鎖モノクローナル抗体又はその抗体断片、及び前記標識化抗体又は標識化抗体断片からなる免疫複合体を生成させ、生成した前記免疫複合体中の標識量を測定する、検体中のα2,6糖鎖の免疫学的測定方法等が挙げられる。
Siaα2-6Galβ1-4GlcNAc-BSAを免疫原として、ウサギ(slc:JW/CSK、13週齢)に免疫し、得られたウサギB細胞について、Siaα2-6Galβ1-4GlcNAcに結合する細胞(シングルセル)をELISA法により試験し、27個の陽性クローンを選択した。選択された陽性クローンから、シングルセルPCRにより、抗体遺伝子を取得した。得られた抗体遺伝子配列をヒト胎児腎細胞293(Human Embryonic Kidney cells 293)細胞にトランスフェクションし、培養上清に分泌された組み換えウサギ抗体について、α2,6糖鎖及びα2,3糖鎖との結合性を、以下のELISA法により確認し、α2,6糖鎖に結合性が高く、α2,3糖鎖に結合性が低い5個の抗体(8A2、8A4、8B5、8B9、8B19)を得た。図1に、これら5個の抗体のELISA試験の結果を示す。
96wellプレートにSiaα2,6Gal抗原BSA-MBS-ペプチド結合物(BSA-MBS-シアル酸α(2,6)β1,4GlcNAc)を1μl/ml(×2500)で50μl添加し、37℃で1時間インキュベートし、抗原をプレートにウェル上に固定化した。PBST(0.05%Tween20を含むリン酸緩衝生理食塩水(PBS))で3回洗浄後、1%BSA/PBSを100μl添加し、4℃で一晩振とうし、ブロッキングした。PBSTで3回洗浄後、実施例1で得られた各クローンの培養上清を2倍希釈し、50μl添加し、室温で1時間、振とうした。PBSTで3回洗浄後、anti-Rabbit IgG HRP(×10000;ab97080、abcam社製)50μlを添加し、室温で1時間、振とうした。PBSTで3回洗浄後、TMBsubstrate solution(組成:3.3’,5.5’-tetramethylbenzidine、カタログナンバー:N301,ThermoFisher scientific社製)を100μl/well添加し、5分間インキュベートした。次に、0.1N HClを100μl/well添加し、450nmにおける吸光度を測定した。
Siaα2,6Gal抗原BSA-MBS-ペプチド結合物の代わりに、Siaα2,3Gal抗原BSA-MBS-ペプチド結合物を用いる以外は上記と同様に行い、450nmにおける吸光度を測定した。
実施例1で得られたモノクローナル抗体のうち、8A2抗体及び8B9抗体のKD値を以下のようにして算出した。
Amino reactiveバイオセンサー(AR2G;FORTEBIO社製)を超純水で親水化し、20μg/mLのBSA-MBS-シアル酸α(2,3)β1,4GlcNAc抗原溶液、又は、BSA-MBS-シアル酸α(2,6)β1,4GlcNAc抗原溶液に10分間浸漬し、各抗原をセンサーに固定化した。EDC-/sNHS溶液(組成:1-ethyl-3-(3-dimethylaminopropyl)carbodiimide(FORTEBIO社製)とsulfo-N-hydroxysuccinimide(FORTEBIO社製)とを1:1で混合)にセンサーを浸漬し、ブロッキングした。BSA-MBS-β1,4GlcNAc抗原固定化センサーは、ブロッキング後にシアリダーゼ溶液(組成:3μL α(2→3,6,8,9)Neuraminidase from Arthrobacter ureafaciens(N3786-1SET、Sigma社製)+47μL 100mM acetate buffer(pH5.5))に37℃、3時間浸漬し、シアル酸を遊離させて作製した。PBSで洗浄後、30℃条件下で、3.75から60nMの各抗体溶液中にバイオセンサーを300秒間浸漬し、抗原への抗体の結合状態を測定した。その後、PBSに300秒間浸漬し、抗原からの抗体の解離状態を測定した。バイオセンサーに結合する抗体、またはバイオセンサーから解離する抗体数の変化によって生じる波長シフトΔλの変化を、リアルタイムに計測し、Octetシステム上(FORTEBIO社製)で反応プロファイルを生成した。3.75nMから60nMの各濃度の抗体溶液中で得られた結合および解離のセンサーグラムから、KD値を算出した。算出されたKD値を表3に示す。また、8A2抗体、8B9抗体の上記センサーグラムの結果を、それぞれ図2A~図2C、図3A~図3Cに示す。
Claims (8)
- 末端シアル酸残基がα2,6結合でガラクトースに結合した糖鎖に特異的に結合し、末端にシアル酸が結合していないガラクトースが結合した糖鎖に結合しない、モノクローナル抗体又はその抗体断片。
- 末端シアル酸残基がα2,6結合でガラクトースに結合した糖鎖との解離定数が、1.0×10-8以下である、請求項1に記載のモノクローナル抗体又はその抗体断片。
- 末端シアル酸残基がα2,6結合でガラクトースに結合した糖鎖との結合性が、末端シアル酸残基がα2,3結合でガラクトースに結合した糖鎖との結合性よりも20倍以上高い、請求項1又は2に記載のモノクローナル抗体又はその抗体断片。
- 前記抗体又はその抗体断片の重鎖可変領域(以下、VHとも称する)の相補性決定領域(Complementarity determining region;以下、CDRとも称する)1のアミノ酸配列が、配列番号1で表されるアミノ酸配列を含み、VHのCDR2のアミノ酸配列が、配列番号2で表されるアミノ酸配列を含み、VHのCDR3のアミノ酸配列が、配列番号3で表されるアミノ酸配列を含み、軽鎖可変領域(以下、VLとも称する)のCDR1のアミノ酸配列が、配列番号4で表されるアミノ酸配列を含み、VLのCDR2のアミノ酸配列が、配列番号5で表されるアミノ酸配列を含み、VLのCDR3のアミノ酸配列が、配列番号6で表されるアミノ酸配列を含む、請求項1~3のいずれか1項に記載のモノクローナル抗体又はその抗体断片。
- 前記抗体又はその抗体断片のVHのアミノ酸配列が、配列番号13で表されるアミノ酸配列を含み、VLのアミノ酸配列が、配列番号14で表されるアミノ酸配列を含む、請求項4に記載のモノクローナル抗体又はその抗体断片。
- 前記抗体又はその抗体断片のVHのCDR1のアミノ酸配列が、配列番号7で表されるアミノ酸配列を含み、VHのCDR2のアミノ酸配列が、配列番号8で表されるアミノ酸配列を含み、VHのCDR3のアミノ酸配列が、配列番号9で表されるアミノ酸配列を含み、VLのCDR1のアミノ酸配列が、配列番号10で表されるアミノ酸配列を含み、VLのCDR2のアミノ酸配列が、配列番号11で表されるアミノ酸配列を含み、VLのCDR3のアミノ酸配列が、配列番号12で表されるアミノ酸配列を含む、請求項1~3のいずれか1項に記載のモノクローナル抗体又はその抗体断片。
- 前記抗体又はその抗体断片のVHのアミノ酸配列が、配列番号15で表されるアミノ酸配列を含み、VLのアミノ酸配列が、配列番号16で表されるアミノ酸配列を含む、請求項6に記載のモノクローナル抗体又はその抗体断片。
- 請求項1~7のいずれか1項に記載のモノクローナル抗体又はその抗体断片を用いる、末端シアル酸残基がα2,6結合でガラクトースに結合した糖鎖の測定方法。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2021/011037 WO2022195797A1 (ja) | 2021-03-18 | 2021-03-18 | 末端シアル酸残基がα2,6結合でガラクトースに結合した糖鎖に特異的に結合するモノクローナル抗体、及び、末端シアル酸残基がα2,6結合でガラクトースに結合した糖鎖の測定方法 |
JP2022539160A JP7246603B2 (ja) | 2021-03-18 | 2021-03-18 | 末端シアル酸残基がα2,6結合でガラクトースに結合した糖鎖に特異的に結合するモノクローナル抗体、及び、末端シアル酸残基がα2,6結合でガラクトースに結合した糖鎖の測定方法 |
EP21931548.8A EP4310100A1 (en) | 2021-03-18 | 2021-03-18 | Monoclonal antibody specifically binding to sugar chain in which a terminal sialic acid residue is bound to galactose with ?2,6 linkage, and method for measuring sugar chain in which terminal sialic acid residue is bound to galactose with ?2,6 linkage |
US18/281,484 US20240151724A1 (en) | 2021-03-18 | 2021-03-18 | Monoclonal antibody specifically binding to sugar chain in which a terminal sialic acid residue is bound to galactose with alpha 2,6 linkage, and method for measuring sugar chain in which terminal sialic acid residue is bound to galactose with alpha 2,6 linkage |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2021/011037 WO2022195797A1 (ja) | 2021-03-18 | 2021-03-18 | 末端シアル酸残基がα2,6結合でガラクトースに結合した糖鎖に特異的に結合するモノクローナル抗体、及び、末端シアル酸残基がα2,6結合でガラクトースに結合した糖鎖の測定方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022195797A1 true WO2022195797A1 (ja) | 2022-09-22 |
Family
ID=83321993
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2021/011037 WO2022195797A1 (ja) | 2021-03-18 | 2021-03-18 | 末端シアル酸残基がα2,6結合でガラクトースに結合した糖鎖に特異的に結合するモノクローナル抗体、及び、末端シアル酸残基がα2,6結合でガラクトースに結合した糖鎖の測定方法 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20240151724A1 (ja) |
EP (1) | EP4310100A1 (ja) |
JP (1) | JP7246603B2 (ja) |
WO (1) | WO2022195797A1 (ja) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07101996A (ja) * | 1993-10-05 | 1995-04-18 | Mect Corp | シアル酸を検出するモノクローナル抗体 |
JP2011529184A (ja) * | 2008-07-25 | 2011-12-01 | ザ・ジョンズ・ホプキンス・ユニバーシティ | Psa糖鎖付加パターンを用いる前立腺癌の検出 |
WO2014057983A1 (ja) * | 2012-10-12 | 2014-04-17 | 国立大学法人弘前大学 | 前立腺癌と前立腺肥大を識別するための方法およびキット |
JP2016088886A (ja) * | 2014-11-05 | 2016-05-23 | 公立大学法人会津大学 | 前立腺癌の検出に有用な単クローン抗体およびその抗体をコードする遺伝子 |
JP6172687B2 (ja) | 2013-05-02 | 2017-08-02 | 国立研究開発法人産業技術総合研究所 | シアリル化糖鎖を認識するモノクローナル抗体 |
-
2021
- 2021-03-18 EP EP21931548.8A patent/EP4310100A1/en active Pending
- 2021-03-18 US US18/281,484 patent/US20240151724A1/en active Pending
- 2021-03-18 WO PCT/JP2021/011037 patent/WO2022195797A1/ja active Application Filing
- 2021-03-18 JP JP2022539160A patent/JP7246603B2/ja active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07101996A (ja) * | 1993-10-05 | 1995-04-18 | Mect Corp | シアル酸を検出するモノクローナル抗体 |
JP2011529184A (ja) * | 2008-07-25 | 2011-12-01 | ザ・ジョンズ・ホプキンス・ユニバーシティ | Psa糖鎖付加パターンを用いる前立腺癌の検出 |
WO2014057983A1 (ja) * | 2012-10-12 | 2014-04-17 | 国立大学法人弘前大学 | 前立腺癌と前立腺肥大を識別するための方法およびキット |
JP6172687B2 (ja) | 2013-05-02 | 2017-08-02 | 国立研究開発法人産業技術総合研究所 | シアリル化糖鎖を認識するモノクローナル抗体 |
JP2016088886A (ja) * | 2014-11-05 | 2016-05-23 | 公立大学法人会津大学 | 前立腺癌の検出に有用な単クローン抗体およびその抗体をコードする遺伝子 |
Non-Patent Citations (11)
Title |
---|
"Current Protocols in Molecular Biology", 1987, JOHN WILEY & SONS |
"Molecular Cloning", 1989, COLD SPRING HARBOR LABORATORY PRESS |
AL-LAZIKANI ET AL., J. MOLEC. BIOL., vol. 273, 1997, pages 927 - 948 |
GENE, vol. 34, 1985, pages 315 |
KABAT ET AL.: "Sequences of Proteins of Immunological interest", 1991, NATIONAL INSTITUTES OF HEALTH |
NAITO, Y.: "Activation-dependent change in sialic acid species in mouse B cells", TRENDS IN GLYCOSCIENCE AND GLYCOTECHNOLOGY, vol. 21, no. 120, 30 November 2008 (2008-11-30), JP , pages 237 - 246, XP009539980, ISSN: 0915-7352, DOI: 10.4052/tigg.21.237 * |
NUCLEIC ACIDS RESEARCH, vol. 10, 1982, pages 6487 |
NUCLEIC ACIDS RESEARCH, vol. 13, 1985, pages 4431 |
PROC. NATL. ACAD. SCI. USA, vol. 79, 1982, pages 6409 |
PROC. NATL. ACAD. SCI. USA, vol. 82, 1985, pages 488 |
TAJIRI MOHYAMA CWADA Y, GLYCOBIOLOGY, vol. 18, 2008, pages 2 - 8 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2022195797A1 (ja) | 2022-09-22 |
US20240151724A1 (en) | 2024-05-09 |
JP7246603B2 (ja) | 2023-03-28 |
EP4310100A1 (en) | 2024-01-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20070166776A1 (en) | Immunoassay and kit for an early and simultaneous detection of biochemical markers in a patient's sample | |
TW200813428A (en) | Antibody pair screening methods | |
WO2022265066A1 (ja) | SARS-CoV-2の免疫測定方法及び免疫測定キット | |
WO2009107170A1 (ja) | 抗crp抗体及びその利用 | |
WO2022265065A1 (ja) | SARS-CoV-2の免疫測定方法及び免疫測定キット、並びにモノクローナル抗体又はその抗体断片 | |
TW201812299A (zh) | 腫瘤標記物之測定方法及測定試藥 | |
TW201812300A (zh) | 心肌肌鈣蛋白之測定方法及測定試藥 | |
JP7153054B2 (ja) | 自己抗体の定量方法 | |
CN108409841B (zh) | 用于检测特异性过敏原IgE的单域结合蛋白及应用 | |
WO2018227643A1 (zh) | 一种用于脂肪性肝炎检测的靶标志物gp73及检测应用方法 | |
RU2607588C2 (ru) | Способ получения агента, связывающегося с препро-вазопрессином или с его фрагментами | |
JP5765635B2 (ja) | Ku86とその自己抗体との複合体の免疫測定方法、それに用いるキット及びそれを用いた癌判定方法 | |
JP7246603B2 (ja) | 末端シアル酸残基がα2,6結合でガラクトースに結合した糖鎖に特異的に結合するモノクローナル抗体、及び、末端シアル酸残基がα2,6結合でガラクトースに結合した糖鎖の測定方法 | |
JP7222501B2 (ja) | 末端シアル酸残基がα2,3結合でガラクトースに結合した糖鎖に特異的に結合するモノクローナル抗体、及び、末端シアル酸残基がα2,3結合でガラクトースに結合した糖鎖の測定方法 | |
JP6317824B2 (ja) | メラトニンの高感度検出 | |
JP6867529B1 (ja) | ヘリコバクター・ピロリ検出用抗体 | |
US11327078B2 (en) | Monoclonal antibody against APOA4, immunological measurement method, and kit for measurement | |
WO2019189940A1 (ja) | 抗原の処理方法。 | |
WO2021193763A1 (ja) | ヒトiv型コラーゲン7sドメインを含む断片の測定方法及びこれに用いるためのキット | |
JP7147997B2 (ja) | 抗8-ヒドロキシ-2’-デオキシグアノシン抗体又はその抗体断片、製造方法、キット、測定方法、及び測定用装置 | |
WO2022202876A1 (ja) | I型コラーゲンc末端テロペプチドの免疫学的分析方法 | |
WO2023068248A1 (ja) | I型コラーゲン架橋n-テロペプチドの免疫測定方法及び免疫測定キット、並びに抗体又はその抗体断片 | |
JP2022122282A (ja) | Dupan-2抗原の測定方法、測定試薬及び測定キット | |
JP2022122283A (ja) | Dupan-2抗原の測定方法、測定試薬及び測定キット | |
CN117192112A (zh) | 一种监测免疫检测采样质量的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 2022539160 Country of ref document: JP Kind code of ref document: A |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21931548 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18281484 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2021931548 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021931548 Country of ref document: EP Effective date: 20231018 |